Program
Nitroglycerin
Also written as “Glyceryl Trinitrate”, “MED2005” and “IMX-150”.
Its studies are mostly in Raynaud Disease · Erectile Dysfunction · Coronary Artery Disease · Fissure in Ano · Connective Tissue Diseases, led by 5 companies.
Drug pageNitroglycerin: every studyMany companies study it; this page follows only the 12 they lead. All 119 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MediQuest Therapeuticsits history only | 40 open or running | phase 3since Dec 18, 2007 | May 29, 2007 | none ahead |
| Futura Medical Developmentsits history only | 30 open or running | phase 3since Jan 15, 2019 | Jun 29, 2015 | none ahead |
| AbbVieits history only | 20 open or running | phase 4since Aug 7, 2013 | Aug 28, 2007 | none ahead |
| Procris Pharmaceuticalsits history only | 20 open or running | phase 2since Mar 17, 2008 | Mar 17, 2008 | none ahead |
| Covis Pharma S.à.r.l. | 10 open or running | phase 2since Feb 18, 2016 | Feb 18, 2016 | none ahead |
Also a collaborator on its studies: Merck and Richmond Pharmacology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Covis Pharma S.à.r.l. only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 18, 2016First study: phase 2 study in Raynaud's Phenomenon Secondary to Connective Tissue DiseaseFirst studyNCT02688270 · 65 enrolled · United States
TargetBeta
“Soluble guanylate cyclase activator”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ataciguatrule | Sanofi | phase 3 | 3 |
| praliciguatrule | Ironwood Pharmaceuticals | phase 2 | 8 |
Studies
The one study Covis Pharma S.à.r.l. leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02688270Raynaud's Phenomenon Secondary to Connective Tissue Disease · United States | 2 | Completed | Dec 2016 | 65 |
How it is read
Names in the registry
- “Nitroglycerin”, 4 entries
- “Glyceryl Trinitrate”, 4 entries
- “MED2005”, 2 entries
- “IMX-150”, 2 entries
- “Nitroglycerin spray”, 1 entry
Conditions, from the studies’ own filings
- Raynaud Disease, 4 studies
- Erectile Dysfunction, 3 studies
- Coronary Artery Disease, 2 studies
- Fissure in Ano, 2 studies
- Connective Tissue Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.